FORMULATION AND IN VITRO EVALUATION OF VILDAGLIPTIN FLOATING TABLETS

The main aim of the present work was to formulate and evaluate Vildagliptin floating tablets. Vildagliptin is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired. The present research work was aimed to design, develop and evaluate floating tablets containing Vildagliptin for controlled release by direct compression method. Various proportions of polymer such as HPMC K 100M was used in all formulations. Optimization of formulation was done by studying effect of drug to polymer ratio on drug release. FT-IR studies indicated absence of any interaction between Vildagliptin and polymer (HPMC K 100M) and excipients. Six formulations were prepared and formulation F6 possessed good floating property with total floating time more than 12 hours. The tablets were also evaluated for its hardness, friability, buoyancy time and In-Vitro drug release test. All parameters complied with IP limits. The optimized formulation was found to be F6 which released 82.88% of drug in 12 h in vitro, while the buoyancy time was 1.16 min. The optimized formulation followed first-order kinetics and Higuchi’s model in drug release. Key words: Floating drug delivery, Vildagliptin, HPMC K100 M, Buoyancy, Controlled releas